Dizal (Jiangsu) Pharmaceutical Co., Ltd.

SHSE:688192 Stock Report

Market Cap: CN¥17.7b

Dizal (Jiangsu) Pharmaceutical Past Earnings Performance

Past criteria checks 0/6

Dizal (Jiangsu) Pharmaceutical's earnings have been declining at an average annual rate of -16%, while the Biotechs industry saw earnings growing at 7.6% annually. Revenues have been growing at an average rate of 75.1% per year.

Key information

-16.0%

Earnings growth rate

-11.9%

EPS growth rate

Biotechs Industry Growth11.3%
Revenue growth rate75.1%
Return on equity-212.3%
Net Margin-214.9%
Last Earnings Update30 Sep 2024

Recent past performance updates

Recent updates

Dizal (Jiangsu) Pharmaceutical Co., Ltd.'s (SHSE:688192) Share Price Could Signal Some Risk

Dec 24
Dizal (Jiangsu) Pharmaceutical Co., Ltd.'s (SHSE:688192) Share Price Could Signal Some Risk

Health Check: How Prudently Does Dizal (Jiangsu) Pharmaceutical (SHSE:688192) Use Debt?

Aug 20
Health Check: How Prudently Does Dizal (Jiangsu) Pharmaceutical (SHSE:688192) Use Debt?

Dizal (Jiangsu) Pharmaceutical Co., Ltd. (SHSE:688192) Analysts Just Slashed This Year's Revenue Estimates By 12%

May 02
Dizal (Jiangsu) Pharmaceutical Co., Ltd. (SHSE:688192) Analysts Just Slashed This Year's Revenue Estimates By 12%

Is Dizal (Jiangsu) Pharmaceutical (SHSE:688192) Using Too Much Debt?

Apr 30
Is Dizal (Jiangsu) Pharmaceutical (SHSE:688192) Using Too Much Debt?

Revenue & Expenses Breakdown

How Dizal (Jiangsu) Pharmaceutical makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

SHSE:688192 Revenue, expenses and earnings (CNY Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 24390-837563790
30 Jun 24295-938521840
31 Mar 24173-1,092471849
31 Dec 2391-1,108438801
30 Sep 2340-1,055365759
30 Jun 230-905274675
31 Mar 230-794198649
31 Dec 220-736128661
30 Sep 224-714107657
30 Jun 227-71696656
31 Mar 2210-71692633
31 Dec 2110-67088584
30 Sep 2111-59378501
31 Dec 2028-587340424
31 Dec 1941-44647409
31 Dec 1839-17433197

Quality Earnings: 688192 is currently unprofitable.

Growing Profit Margin: 688192 is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: 688192 is unprofitable, and losses have increased over the past 5 years at a rate of 16% per year.

Accelerating Growth: Unable to compare 688192's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: 688192 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (1.3%).


Return on Equity

High ROE: 688192 has a negative Return on Equity (-212.33%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/25 16:24
End of Day Share Price 2024/12/25 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Dizal (Jiangsu) Pharmaceutical Co., Ltd. is covered by 8 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Pei ChengChina Galaxy Securities Co., Ltd.
Ziyu HeChina International Capital Corporation Limited
Jin ZhangChina International Capital Corporation Limited